Ferric citrate: A novel phosphate-binding agent

Expert Review of Endocrinology and Metabolism

Volumn 8, Issue 1, 2013, Pages 13-19

  Umanath, Kausik ^a   Niecestro, Robert ^b   Lewis, Julia B ^c   Dwyer, Jamie P ^c  

^a HENRY FORD HOSPITAL   (United States)

^b Independent Consultant   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CKD MBD; ESRD; iron metabolism; metabolic acidosis; phosphate binder

Indexed keywords

CITRIC ACID; FERRIC CITRATE; FERRIC ION; KRX 0502; PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

EID: 84871577551     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.12.66     Document Type: Article

References (33)

1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. Suppl. 73, S14-S19 (1999
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15(8), 2208-2218 (2004
3. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42(4 Suppl. 3), S1-S201 (2003
4. • Kidney Disease Outcomes Quality Initiative and Kidney Disease Improving Global Outcomes practice guidelines for chronic kidney disease-associated mineral and bone disorders. 4 Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 113, S1-S130 (2009
5. Molony DA, Murthy B. Accumulation of metals and minerals from phosphate binders. Blood Purif. 23(Suppl. 1), 2-11 (2005
6. Clarkson EM, Durrant C, Phillips ME, Gower PE, Jewkes RF, de Wardener HE. The effect of a high intake of calcium and phosphate in normal subjects and patients with chronic renal failure. Clin. Sci. 39(6), 693-704 (1970
7. Clarkson EM, Eastwood JB, Koutsaimanis KG, de Wardener HE. Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int. 3(4), 258-263 (1973
8. Clarkson EM, McDonald SJ, De Wardener HE. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin. Sci. 30(3), 425-438 (1966
9. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am. J. Kidney Dis. 29(4), 641-649 (1997
10. McDonald SJ, Clarkson EM, Dewardener HE. The effect of a large intake of calcium citrate in normal subjects and patients with chronic renal failure. Clin. Sci. 26, 27-39 (1964
11. How PP, Fischer JH, Arruda JA, Lau AH. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin. J. Am. Soc. Nephrol. 2(6), 1235-1240 (2007
12. Feng L, Xiao H, He X et al. Neurotoxicological consequence of long-term exposure to lanthanum. Toxicol. Lett. 165(2), 112-120 (2006
13. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 68(6), 2809-2813 (2005
14. [No authors listed]. Sevelamer reduces the efficacy of many other drugs. Prescrire. Int. 18(102), 164-165 (2009
15. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am. J. Kidney Dis. 42(6), 1253-1259 (2003
16. Liu SH, Chu HI, Hsu HC, Chao HC, Cheu SH. Calcium and phosphorus metabolism in osteomalacia. XI. the pathogenetic role of pregnancy and relative importance of calcium and vitamin D supply. J. Clin. Invest. 20(3), 255-271 (1941
17. Liu SH, Chu HI. Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (A.T. 10) and iron. Medicine (Baltimore) 22, 103-161 (1943
18. Fleming RE, Ponka P. Iron overload in human disease. N. Engl. J. Med. 366(4), 348-359 (2012
19. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol. Dial. Transplant. 17(2), 265-270 (2002
20. Sinsakul MV, Korbet S, Greene T et al. The safety and tolerability of higher doses of ferric citrate in controlling serum phosphorus in ESRD patients. Poster Presented at: National Kidney Foundation Meetings. Orlando, FL, USA (2010
21. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am. J. Kidney Dis. 47(5 Suppl. 3), S16-S85 (2006
22. Kidney Disease Outcomes Quality Initiative. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am. J. Kidney Dis. 50(3), 471-530 (2007
23. Sika M, Smith M, Schulman G, Kaplan M, Lewis JB. A dose-ranging and efficacy Phase 3 trial of ferric citrate (FC) as a phosphate binder in dialysis patients. Am. J. Kid. Dis. (2011) (Abstract 292
24. Umanath K, Sika M, Niecestro RM et al. Rationale and study design of a threeperiod, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial. Int. doi:10.1111/j.1542-4758.2012.00711.x (2012) (Epub ahead of print
25. Finn WF; SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients. Clin. Nephrol. 65(3), 191-202 (2006
26. Joy MS, Finn WF; LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. 42(1), 96-107 (2003
27. Slatopolsky EA, Burke SK, Dillon MA RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 55(1), 299-307 (1999
28. Van Wyck DB. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: Strategies for assessment and management. Semin. Nephrol. 9(1 Suppl. 2), 21-24 (1989
29. Sika M, Sinsakul MV, Niecestro RM, Chiang S. Prolonged use of ferric citrate (FC) as a phosphate binder reduces IV iron use in Pts with ESRD. Presented at: Renal Week. Denver, CO, USA, 16-21 November 2010 (Abstract SA-PO2946
30. Sinsakul MV, Sika M, Koury M et al. Iron absorption with higher doses of ferric citrate in controlling serum phosphorus in ESRD patients. Presented at: National Kidney Foundation Meeting (2010) (Abstract
31. Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 44(4), 661-671 (2004
32. Wu DY, Shinaberger CS, Regidor DL, McAllister CJ, Kopple JD, Kalantar-Zadeh K. Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic? Clin. J. Am. Soc. Nephrol. 1(1), 70-78 (2006
33. Gennari FJ. Very low and high predialysis serum bicarbonate levels are risk factors for mortality: what are the appropriate interventions? Semin. Dial. 23(3), 253-257 (2010